Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Supports Expanded Indications For Medtronic CRT-D Devices

This article was originally published in The Gray Sheet

Executive Summary

Despite data concerns, FDA’s Circulatory System Devices advisory panel favors expanding the indications for Medtronic cardiac resynchronization therapy-defibrillator devices to allow treatment of heart failure patients with milder symptoms.

You may also be interested in...



New Products In Brief

The latest product approvals and launches in cardiology, ophthalmology and more.

Boston Scientific Gains Expanded Indication For CRT-D Devices

Boston Scientific hopes its newfound ability to legally market its cardiac resynchronization therapy defibrillators for use in a broader heart failure population will help its efforts to regain lost market share in the sector

FDA Panel Endorses Expanded Approval For Boston Scientific CRT-Ds

Boston Scientific's cardiac resynchronization therapy defibrillators (CRT-Ds) should be approved for use in some healthier heart failure patients, though not quite as many as the company initially proposed, an FDA advisory panel said March 18

Topics

UsernamePublicRestriction

Register

MT030796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel